FY2025 · ended Dec 31, 2025 · Revenue $62.38M, +48.3% YoY · Filed Mar 5, 2026
Tango Therapeutics, Inc. (TNGX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $62.4 million and a net loss of $101.6 million. Free cash flow was -$139.9 million. As of Jun 30, 2026 it held $1.0 billion in cash and investments and $32.0 million in total debt.
Revenue (TTM)
$53.81M
+121.5% vs year-ago TTM
Net income (TTM)
$-123.72M
+15.0% vs year-ago TTM
Operating cash flow (TTM)
$-143.90M
+2.9% vs year-ago TTM
Free cash flow (TTM)
$-144.25M
+3.3% vs year-ago TTM
EPS (TTM)
$-0.92
+30.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
142.69M
+32.0% vs prior year
Net cash
$982.00M
as of Jun 30, 2026
Operating margin
-253.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1819133
- Former names
- BCTG Acquisition Corp. (until Aug 9, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M |
| Operating income | -$111.3M | -$145.6M | -$114.2M | -$111.1M | -$58.2M |
| Net income | -$101.6M | -$130.3M | -$101.7M | -$108.2M | -$58.2M |
| Diluted EPS | -$0.87 | -$1.19 | -$1.08 | -$1.23 | — |
| Operating cash flow | -$138.9M | -$131.5M | -$118.0M | -$109.1M | -$59.5M |
| Free cash flow | -$139.9M | -$132.3M | -$119.5M | -$116.8M | -$61.4M |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M |
| Total liabilities | $52.5M | $117.0M | $149.5M | $187.0M | $155.4M |
| Stockholders' equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M |
| Cash and investments | $343.1M | $257.9M | $336.9M | $366.1M | $485.3M |
| Total debt | $33.6M | $36.5M | $36.5M | $41.1M | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Aug 7, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 6, 2026 | Jul 31, 2026 |
All 424 Tango Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.